Dry Eye Disease | Treatment Algorithms: Claims Data Analysis | US | 2024
Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. For 13 years, AbbVie’s Restasis was the only FDA-approved therapy for DED, until the launch of novel agents, including Bausch + Lomb’s Xiidra, Restasis MultiDose, Sun Ophthalmics’ Cequa, Alcon’s Eysuvis, and Viatris’s Tyrvaya. In addition, in May 2023, the FDA approved Bausch + Lomb / Novaliq’s Miebo, the first and only agent specifically approved to treat evaporative DED. Apart from conservative measures (e.g., lid hygiene, artificial tears), the management of DED also includes the prescription of off-label ophthalmic corticosteroids and antibiotics. This claims data analysis gives manufacturers of current treatments, as well as those developing novel agents, real-world insight into recent trends in the use of drugs for DED.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DED patients?
- How have Eysuvis and Tyrvaya been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of DED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DED patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Bausch + Lomb, Sun Ophthalmics, Kala Pharmaceuticals, Alcon, Viatris, Novaliq
Key drugs: Restasis, Restasis MultiDose, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo
Key analysis provided
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flowcharts
